Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising therapeutic option for people with arthritis and obesity or type 2 diabetes mellitus owing to their pleiotropic effects, including weight loss, improved survival and reduced risk of major cardiovascular and renal events
Two studies demonstrated that L-carnitine can improve liver function and prognosis in patients with liver cancer after surgery (68, 106)
Broader lifestyledriven risk factors, rising obesity rates, and earlier onset of metabolic disorders are intensifying the pressure on the healthcare system to expand access to effective antidiabetic medicines
Variants in GLP1R (the GLP-1 receptor gene itself), FTO , MC4R , and TCF7L2 all relate to GLP-1 and adjacent signaling
Melanie Cree, director of the multidisciplinary PCOS Clinic at Children's Hospital Colorado